Structure-based Virtual Screening and Identification of a Novel Androgen Receptor Antagonist*5

Chin-Hee Song†1, Su Hui Yang§1, Eunsook Park‡, Suk Hee Cho†, Eun-Young Gong‡, Daulat Bikram Khadka§, Won-Jea Cho§2, and Keeook Lee†3

Received for publication, May 6, 2012, and in revised form, July 12, 2012. Published, JBC Papers in Press, July 13, 2012, DOI 10.1074/jbc.M112.379107

From the †Hormone Research Center, School of Biological Sciences and Technology and the §College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea

Background: The androgen receptor (AR) is the primary drug target for prostate cancer treatment.

Results: We have identified a novel AR antagonist, the compound 6-(3,4-dihydro-1H-isooquinolin-2-yl)-N-(6-methylpyridin-2-yl)nicotinamide (DIMN) that inhibits the growth of AR-positive prostate cancer cells.

Conclusion: DIMN has been identified as a new lead structure targeting the AR.

Significance: This novel AR antagonist could be a useful therapeutic agent for prostate cancer treatment.

Hormonal therapies, mainly combinations of anti-androgens and androgen deprivation, have been the mainstay treatment for advanced prostate cancer because the androgen-androgen receptor (AR) system plays a pivotal role in the development and progression of prostate cancers. However, the emergence of androgen resistance, largely due to inefficient anti-hormone action, limits the therapeutic usefulness of these therapies. Here, we report that 6-(3,4-dihydro-1H-isooquinolin-2-yl)-N-(6-methylpyridin-2-yl)nicotinamide (DIMN) acts as a novel anti-androgenic compound that may be effective in the treatment of both androgen-dependent and androgen-independent prostate cancers. Through AR structure-based virtual screening using the FlexX docking model, fifty-four compounds were selected and further screened for AR antagonism via cell-based tests. One compound, DIMN, showed an antagonistic effect specific to AR with comparable potency to that of the classical AR antagonists, hydroxyflutamide and bicalutamide. Consistent with their anti-androgenic activity, DIMN inhibited the growth of androgen-dependent LNCaP prostate cancer cells. Interestingly, the compound also suppressed the growth of androgen-independent C4–2 and CWR22Rv prostate cancer cells, which express a functional AR, but did not suppress the growth of the AR-negative prostate cancer cells PPC-1, DU145, and R3327-AT3.1. Taken together, the results suggest that the synthetic compound DIMN is a novel anti-androgen and strong candidate for useful therapeutic agent against early stage to advanced prostate cancer.

Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer deaths in men in the United States (1, 2). It is well established that androgens, such as testosterone and dihydrotestosterone (DHT), play an essential role in the tumorigenesis and progression of androgen-dependent early stage prostate cancer (3). Testosterone, predominantly produced by Leydig cells in the testes, is converted to a more active form, DHT, by the enzyme 5α-reductase in the prostate. Early onset prostate cancer is androgen-dependent; therefore, androgen-ablation therapies that decrease the levels of circulating androgens through chemical or surgical castration have been the mainstay of treatment for androgen-dependent prostate cancer (ADPC). Unfortunately, androgen-ablation therapy is only palliative. After 2–3 years of treatment, the cancer cells progress to a more aggressive form, androgen-independent prostate cancer (AIPC), or to a hormone refractory state known as castration-resistant prostate cancer (CRPC) (4, 5).

The androgen receptor (AR), the mediator of androgen action, is a member of the steroid hormone receptor superfamily and contains a DNA-binding domain and a hormone-binding domain. This receptor is activated by binding with androgens in the cytoplasm and is then translocated into the nucleus, where it regulates the expression of target genes such as prostate-specific antigen (PSA) and NK3 transcription factor locus 1 (NKK3.1) in the human prostate. AR signaling is known to regulate the development and progression of normal, benign, and malignant prostate cells (6–8). The AR is expressed in the vast majority of both ADPC and AIPC, and decreasing levels of AR protein expression reduce both ADPC and AIPC growth, suggesting a critical role of AR signaling in both types of prostate cancers (9–11). Castration resistance is attributed to the high expression of the AR and AR-regulated genes, indicating

* This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (NRF-2012R1A2A2A01008388, NRF-2011-0015551).

† This article contains supplemental Figs. S1 and S2.

‡ Both authors contributed equally to this work.

†1 To whom correspondence may be addressed: College of Pharmacy, Chonnam National University, Gwangju 500-757, Republic of Korea. Tel.: 82-62-530-2933; Fax: 82-62-530-2911; E-mail: wjcho@chonnam.ac.kr.

‡2 To whom correspondence may be addressed: Hormone Research Center, Chonnam National University, Gwangju, 500-757, Republic of Korea. Tel.: 82-62-530-0509; Fax: 82-62-530-0500; E-mail: klee@chonnam.ac.kr.

§ The abbreviations used are: DHT, dihydrotestosterone; AR, androgen receptor; OHF, hydroxyflutamide; BIC, bicalutamide; DIMN, 6-(3,4-dihydro-1H-isooquinolin-2-yl)-N-(6-methylpyridin-2-yl)nicotinamide; ADPC, androgen-dependent prostate cancer; AIPC, androgen-independent prostate cancer; CRPC, castration-resistant prostate cancer; HTS, high-throughput screening; VS, virtual screening; RMSD, root-mean-square deviation; LBD, ligand-binding domain.
that AR transcriptional activity is reactivated. AR reactivation in CRPC can be explained by AR gene amplification (12, 13), AR gene mutation (14–17), activation by alternative androgens (18, 19), or ligand-independent AR activation through other factors, including the increased expression of transcriptional co-activators or the activation of kinases and signal transduction pathways that modulate AR function (7, 20–23).

Because of the critical role of the AR in prostate cancer, the AR has been the primary target for the treatment of this disease, and AR antagonists have been used for the treatment of prostate cancer and prostatic hyperplasia. There are two types of AR antagonists, structure-based steroidal and non-steroidal. Cyproterone acetate, one of the steroidal AR antagonists, inhibits androgen action, but it also has weak progesterational and glucocorticoid activities (24, 25). Non-steroidal AR antagonists, such as flutamide (hydroxyflutamide) and bicalutamide, have been considered to be less problematic due to their selective blockade of androgen action and fewer side effects (26–28). Bicalutamide is the most widely used of these compounds in the treatment of prostate cancer because it is believed to overcome some problems caused by other anti-androgens (29). However, because the classical AR antagonists are not effective for the treatment of advanced prostate cancers, many efforts have been undertaken to develop newer and better AR antagonists that work effectively on either early stage androgen-dependent or later stage androgen-independent prostate cancer cells.

Searching for new lead scaffolds that induce equal or better biological responses than the current drugs through the same receptor is a challenging goal in drug design. Because new therapeutic targets and their three-dimensional structures have been identified at a dramatic rate, computational screening methods have become quite reliable as a source of chemical starting points in the drug design/discovery process. Compared with the conventional high-throughput screening (HTS) method, virtual screening (VS) extends the screening possibilities to molecules that do not exist physically in the collection but can be purchased. In addition, out of the large number of chemicals screened in silico, only a small subset of chemicals is tested to quantify biological activity based on the computational prediction results. These substantial advantages have made the VS approach increasingly valuable for the identification of novel lead scaffolds that bind to ligand-dependent receptors (30, 31).

Many trials have been conducted to identify new leads for the development of better AR antagonists that could provide new treatments for prostate cancers. Most of the AR antagonists that have been discovered thus far have been developed through ligand-based drug design, which relies on the pharmacophores of known drugs. Because of the characteristics of ligand-based design, most AR antagonists seem to contain the same basic scaffolds as the known drugs, such as bicalutamide and flutamide or other non-steroidal AR agonists (32, 33). As an example, MDV3100, now in phase III clinical trials, was developed from the non-steroidal AR agonist RU59063 by modifying the chemical structures systemically while maintaining the key chemical scaffold (34).

In this study, keeping in mind the possible switch from AR antagonism to agonism induced by similar scaffolds to those of known ligands, we carried out AR structure-based virtual screening to discover a novel chemical scaffold for AR antagonists. We have successfully identified a new lead structure targeting the AR, and verified the biological effects of the compound as AR antagonist that works on early stage prostate cancer cells as well as on late stage cells.

**EXPERIMENTAL PROCEDURES**

**Chemistry**—Chemicals were purchased from Aldrich Chemical Co. or Tokyo Chemical Industry Co. Melting points were determined by the capillary method on Electrothermal IA9200 digital melting point apparatus. $^1$H NMR data were collected on a Varian 300 FT spectrometer and were calibrated with tetramethysilane. The NMR data are displayed as follows: chemical shifts (δ) are recorded in ppm, coupling constants (J) in hertz (Hz), integrity in the number of protons, and multiplicity in s (singlet), d (doublet), t (triplet), and m (multiplet). Mass spectra were obtained on a Shimadzu LCMS-2010EV utilizing the electron-spray ionization (ESI) method and on a JEOI JNS-DX 303 using the electron-impact (EI) method. IR spectra were recorded on a JASCO-FT IR spectrometer using CHCl$_3$ or Kbr pellets. Thin-layer chromatography (TLC) was carried out using plates coated with silica gel 60 F$_{254}$ purchased from Merck. Column chromatography was performed with Merck silica gel 60 (70–230 mesh).

**Chemical Synthesis of DIMN**—DIMN was prepared in three steps starting from 6-chloro-nicotinic acid (1) (Fig. 1B). Nicotinic acid chloride, formed by refluxing (1) with thionyl chloride, was treated with pyridylamine (2) to obtain the intermediate (3) with 83% yield. Finally, an S$_2$Ar reaction with 1,2,3,4-tetrahydroisoquinoline (4) in 2-propanol under reflux conditions provided the desired DIMN (5) with 72% yield.

**Reagents**—Cyproterone acetate (CPA), bicalutamide (BIC), and 2-hydroxyflutamide (OHF) were purchased from Sigma, Sequoia Research Products Ltd., and LKT Laboratories, Inc., respectively. Radiolabeled dihydrotestosterone ($[^3]$H[DHT]) ($[^1]$,2,4,5,6,7-$[^3]$H[AR]-dihydrotestosterone (5α-androstan-17β-ol-3-one)) and thymidine ([methyl-$[^3]$H]thymidine, specific activity: 70–90 Ci (2.59–3.33 T Bq/mmol) were obtained from Perkin Elmer Life Science. Antibodies were purchased from Santa Cruz Biotechnology, Inc. (AR (sc-815), PSA (sc-7638) and α-tubulin (sc-5286)) and Epitomics, Inc. (GAPDH (cat. #2251-1)).

**Plasmids**—The mammalian expression plasmids of the mouse AR (pcDNA3.AR), mouse GR (pcDNA3.GR), pARE$_2$-TATA-Luc, PSA-Luc, MMTV-Luc, GFP-AR, pCR3.1-SRC1, and pSG5-HA-GRIP-1 (SRC-2) have been previously described (35–40). The pcDNA3.ERα (human ERα expression plasmid) and ERE-Luc reporter constructs were kindly provided by Dr. J. W. Lee (Baylor College of Medicine) (41). The mammalian expression plasmids VP-AR1-660, GAL-AR624-919, and 5XGAL4-Luc3 (originally from Dr. Donald McDonnell) were kindly provided as gifts by Dr. Elizabeth M. Wilson (University of North Carolina) (42).

**Cell Culture**—COS-7, 293T, PPC-1, DU145, HeLa, and MEF (mouse embryonic fibroblast) cells were maintained in Dulbecco’s minimum essential medium (HyClone) supplemented with 10% fetal bovine serum (FBS). LNCaP cells were purchased from the American Type Culture Collection (ATCC CRL-
**Receptor-based Discovery of a Novel AR Antagonist**

A key feature of ligand-dependent receptors for use in rational drug design is the ligand-binding domain (LBD), which we have used in AR structure-based drug discovery. Crystal structures of the AR LBD bound to ligands have been determined, but no structural information about the nature of the antagonist-induced conformational change exists because of the lack of defined crystallization of the wild-type AR-antagonist complex to date. We therefore selected the structure of the AR-metribolone (R1881) complex for screening (code from Protein Data Bank: 1E3G). Since R1881 is one of the compounds known to bind most tightly to the AR, the bound LBD structure would be expected to offer some information on the native AR in its strongest binding state.

A chemical library containing over 200,000 drug-like molecules extracted from commercial and in-house databases was docked into the AR LBD using the docking algorithm FlexX. The binding affinity between the chemicals and the AR LBD was predicted by five different scoring functions and a consensus score. To verify the prediction confidence of our docking system, a root-mean-square deviation (RMSD) calculation was performed by taking into account the binding coordinate of R1881 in the AR LBD. The use of FlexX resulted in the RMSD value of 0.721, which is almost identical to the RMSD value of the native AR-R1881 structure, indicating that our docking program is highly confident. Following the screening, 54 compounds were acquired and numbered in order of their consensus scores (data not shown).

1740). C4–2 and CWR22rv cells were kindly provided by Dr. C. Jung (Chonnam National University Medical School, Republic of Korea). LNCaP, C4–2, and CWR22rv cells were maintained in RPMI 1640 (Hyclone) medium supplemented with 5% FBS. R3327-AT3.1 cells were kindly provided by Mazence, Inc., (Suwon, Republic of Korea) and were maintained in RPMI 1640 (Hyclone) medium supplemented with 10% FBS. All cells were cultured at 37°C in a 95% humidified atmosphere containing 5% CO₂.

**Transient Transfection Assay**—Transfections were carried out using the SuperFect (Qiagen) transfection reagent for COS-7 and 293T cells and the Lipo2000 transfection reagent for PPC-1 cells, according to the instructions of the manufacturer. Cells plated in 24-well plates were transfected with the indicated expression plasmids and a reporter plasmid, along with the β-gal expression plasmid pCMV-β (Clontech). Cells kept in 5% charcoal-stripped FBS (CS) were treated with chemicals in the presence or absence of the ligand for 24 h and processed as described previously (43). The levels of luciferase activity were normalized to β-gal expression.

**Competitive Steroid Binding Assay**—The whole-cell binding assay was performed as described previously (44). Briefly, COS-7 cells were transiently transfected with pcDNA3.AR. Twenty-four hours prior to the binding reaction, the cells were placed in phenol red-free DMEM supplemented with 5% CSS and incubated for 2 h at 37°C with 5 nM 5α-[3H]DHT in the presence and absence of increasing concentrations of unlabeled chemicals. Nonspecific binding of 5α-[3H]DHT was assessed by adding a 100-fold molar excess of unlabeled 5α-DHT. Dose-response data were analyzed using the sigmoidal dose-response function of Prism (GraphPad, San Diego, CA).

**Fluorescent Microscopy**—HeLa cells plated onto 0.1% gelatin-coated coverslips were transfected with the GFP-AR expression vector. After 16 h, transfected cells were fed with fresh DMEM containing 5% CSS and treated for 1 h with chemicals. Cells were processed for fluorescent microscopy using an Olympus 1 × 70 fluorescent microscope (Tokyo, Japan) as described previously (44).

**Northern Blot Analysis**—Northern blot analysis was conducted as described previously (45). Random-primed α-32P-labeled PSA, NkX3.1, and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) cDNA probes were used for hybridization. GAPDH expression was used as an internal control.

**Western Blot Analysis**—Western blot analysis was conducted as described previously (46). In brief, the LNCaP and C4–2 cells were incubated in RPMI supplemented with 5% CSS for 2 days, and then treated with AR antagonists in the presence of 10 nM or 1 nM DHT for 2 days, respectively (47). The whole cell lysates were separated by SDS-PAGE, transferred to nitrocellulose and subjected to Western blot analysis with anti-AR, anti-PSA, anti-α-tubulin, and anti-GAPDH antibodies. Signals were detected using an ECL kit (Amersham Biosciences Pharmacia).

**Thymidine Incorporation Assay**—The thymidine incorporation assay was conducted as described previously (37). LNCaP cells were seeded into 96-well plates at a density of 2 × 10³ cells per well. The cells were treated with chemicals in the presence of 1 nM DHT for 72 h and then treated with 10 μCi/ml of [3H]thymidine for another 4 h. Cells were harvested onto a glass microfiber filter (Whatman, Inc., Florham Park, NJ) and processed for the measurement of incorporated amount of thymidine into DNA. All values represent the mean ± S.E. of at least three independent experiments.

**Cell Viability**—The cell growth and cytotoxicity assays were conducted using the CellTiter 96® aqueous non-radioactive cell proliferation assay kit (Promega). Cells were seeded into 96-well plates at a density of 2 × 10³ cells per well (LNCaP, C4–2, and MEF) or 5 × 10² cells per well (PPC-1, DU145, and R3327-AT3.1). Cells cultured in media supplemented with 5% CSS (LNCaP), 5% FBS (C4–2 and MEF), or 10% FBS (PPC-1, DU145, and R3327-AT3.1) were treated with indicated chemicals for 4 and 6 days. Combined MTS/PMS (ratio 20:1 by volume, 20 μl/well) solution was added to cells in freshly prepared media. After 2 h, the absorbance at 490 nm was recorded using an ELISA plate reader. Cell viability was also assessed by trypan blue dye exclusion by counting cell numbers as described previously (48). CWR22rv cells (4 × 10⁵ cells per well) were incubated with chemicals for 5 days. All values represent the mean ± S.E. of at least three independent experiments.

**Statistical Analysis**—To identify significant differences, the data were analyzed using GraphPad Prism (GraphPad Software, Inc.). Single comparisons between two experimental groups were performed using an unpaired Student’s t test. Data are shown as the means ± S.E. of the mean (S.E.). For all statistical analyses, p < 0.05 was used as the criterion to determine statistical significance.

**RESULTS**

**AR Structure-based Virtual Screening for AR Antagonists**—A chemical library containing over 200,000 drug-like molecules extracted from commercial and in-house databases was docked into the AR LBD using the docking algorithm FlexX. The binding affinity between the chemicals and the AR LBD was predicted by five different scoring functions and a consensus score. To verify the prediction confidence of our docking system, a root-mean-square deviation (RMSD) calculation was performed by taking into account the binding coordinate of R1881 in the AR LBD. The use of FlexX resulted in the RMSD value of 0.721, which is almost identical to the RMSD value of the native AR-R1881 structure, indicating that our docking program is highly confident. Following the screening, 54 compounds were acquired and numbered in order of their consensus scores (data not shown).
To test whether the selected 54 compounds exhibit agonistic/antagonistic activity toward the AR, we performed transient transfection assays using a reporter system for the AR, pARE2-TATA-Luc, which contains two AREs of the androgen target gene C3. The results revealed that several compounds significantly inhibited the DHT-induced transcriptional activation of AR at a concentration of 1 \( \mu \text{M} \) in the presence of 0.3 nM DHT (dihydrotestosterone), 100 nM DXM (dexamethasone), and 10 nM E2 (estradiol), respectively. The repression of AR transactivation by DIMN. The transcriptional activity was determined in COS-7 cells transiently co-transfected with pCDNA3.AR and an androgen-responsive luciferase reporter (pARE2-TATA-Luc, PSA-Luc, or MMTV-Luc). After a 24-h transfection, cells were treated with 1 \( \mu \text{M} \) OHF, CPA, or DIMN in the presence of 0.3 nM DHT for an additional 24 h. OHF and CPA were used as positive controls for AR antagonism. The luciferase data were normalized for \( \beta \)-galactosidase activity and expressed as a percentage of AR activity in the presence of 0.3 nM DHT only. E, dose-dependent AR antagonistic activities of DIMN. After a 24-h transfection with pCDNA3.AR and pARE2-TATA-Luc, COS-7 cells were treated with various concentrations of BIC or DIMN in the presence of 10 nM DHT and incubated for 24 h. The IC\( _{50} \) values represent the concentrations of compounds that inhibited 50% of the response induced by 10 nM DHT. F, agonistic/antagonistic effect of DIMN on AR transactivation. Cells transfected as in E were treated with 10 \( \mu \text{M} \) of DIMN in the absence (white bar) or presence (black bar) of 10 nM DHT. Each value represents the mean ± S.E. of at least three independent experiments. RLU, relative light units.

**Identification of DIMN as a New AR Antagonist** —We first investigated whether the inhibitory effect of DIMN was AR-specific by testing its effect on the transactivation of the steroid receptor GR and ER. COS-7 cells were co-transfected with plas-

---

**FIGURE 1.** Identification of DIMN as a new AR antagonist. A, chemical structures of DIMN and the classical AR antagonists hydroxyflutamide and bicalutamide. B, chemical synthesis of DIMN. C, selective AR antagonist activity of DIMN. D, repression of AR transactivation by DIMN. The transcriptional activity was determined in COS-7 cells transiently co-transfected with pCDNA3.AR and an androgen-responsive luciferase reporter (pARE2-TATA-Luc, PSA-Luc, or MMTV-Luc). After a 24-h transfection, cells were treated with 1 \( \mu \text{M} \) OHF, CPA, or DIMN in the presence of 0.3 nM DHT for an additional 24 h. OHF and CPA were used as positive controls for AR antagonism. The luciferase data were normalized for \( \beta \)-galactosidase activity and expressed as a percentage of AR activity in the presence of 0.3 nM DHT only. E, dose-dependent AR antagonistic activities of DIMN. After a 24-h transfection with pCDNA3.AR and pARE2-TATA-Luc, COS-7 cells were treated with various concentrations of BIC or DIMN in the presence of 10 nM DHT and incubated for 24 h. The IC\( _{50} \) values represent the concentrations of compounds that inhibited 50% of the response induced by 10 nM DHT. F, agonistic/antagonistic effect of DIMN on AR transactivation. Cells transfected as in E were treated with 10 \( \mu \text{M} \) of DIMN in the absence (white bar) or presence (black bar) of 10 nM DHT. Each value represents the mean ± S.E. of at least three independent experiments. RLU, relative light units.
mids expressing the GR and ER along with MMTV-Luc and ERE-Luc, respectively. DIMN specifically inhibited the transactivation of the AR, but not of the GR and ER (Fig. 1C). DIMN was further analyzed for AR antagonistic activity by transient transfection assays using several reporter systems for the AR. The PSA-Luc and MMTV-Luc plasmids contain the prostate specific antigen (PSA) and mouse mammary tumor virus (MMTV) long terminal repeat promoters, respectively, which are natural AR target promoters (35, 49). DIMN inhibited androgen-induced AR transactivation at 1 μM concentration in all of the tested reporter systems (Fig. 1D); this inhibitory potency was similar to that of hydroxyflutamide (OHF). In addition, DIMN inhibited AR transactivation in a dose-dependent manner with the IC_{50} value at 3 μM (Fig. 1E), which is comparable to the IC_{50} value of BIC (1.6 μM). However, even at 10 μM concentration, DIMN showed little agonistic effect in contrast to BIC, which showed some agonistic effect (Fig. 1F) as previously reported (50). These results suggest that DIMN has a strong AR-specific antagonistic effect with little agonistic effect.

Binding of DIMN to AR—To characterize the binding of the compound DIMN to the AR, we performed competitive androgen binding assay using 5α-[3H]DHT (a labeled androgen) and AR expressed in COS-7 cells. We used several known competitors (unlabeled DHT, BIC, and OHF) of DHT as positive controls (38, 51). The IC_{50} (the concentration of ligand that were able to inhibit AR-DHT binding by 50%) of DIMN was 1–2 μM, while the IC_{50} values of unlabeled DHT, OHF, and BIC were 1–2 nM, 0.4–0.5 μM, and 0.9 μM, respectively (Fig. 2A). DIMN showed 2–4-fold lower AR binding activity than OHF and 1–2-
fold lower binding activity than BIC. The compound DIMN could not bind to the AR more tightly than the conventional AR antagonists BIC and OHF, but could bind nearly as well as those antagonists, suggesting that it competes with androgen for AR binding in a similar fashion.

Molecular Basis for the Anti-androgenic Effect of DIMN—Upon ligand binding, AR dissociates from heat shock proteins and translocates into the nucleus, binding to its target gene promoters as a homodimer formed by the intermolecular N/C interaction of two AR molecules. To explore the anti-androgenic effects of DIMN induced through mechanisms other than the inhibition of androgen binding to the AR, we investigated the ability of DIMN to inhibit any of the AR activation steps, such as the N/C interaction, nuclear translocation, and co-activator recruitment.

The effect of DIMN on the AR N/C interaction was tested using a mammalian two-hybrid system. PPC-1 cells were transfected with plasmids encoding the VP-AR1–660 (containing AR residues 1–660) and GAL-AR624–919 (containing AR residues 624–919) fusion proteins in conjunction with a luciferase reporter gene regulated by tandem Gal4-responsive elements (5XGAL4-Luc3) (42). The DHT-induced N/C interaction was inhibited strongly by DIMN. However, its inhibitory effect on the N/C interaction was weaker than that of BIC, which almost completely abolished this interaction (Fig. 2B). The compound induced no N/C interaction of AR in the absence of DHT (Fig. 2B) as OHF and BIC (52, 53). These results suggest that DIMN inhibits the dimerization of the AR.

The elevated expression of SRC-1 and SRC-2 has been reported to enhance AR activity in the development of more aggressive prostate cancers (reviewed in Ref. 57). Therefore, we tested the effects of DIMN on the action of the AR co-activators SRC-1 and SRC-2 via transient transfection assays using a reporter system with pARE2-TATA-Luc. As shown in Fig. 2D, overexpression of SRC-1 and SRC-2 enhanced the transcriptional activity of the AR induced by 10 nM DHT. A 10 μM dose of DIMN could inhibit the SRC-1- and SRC-2-mediated enhancement of AR transactivation. BIC exhibited a similar effect on AR transcriptional activity enhanced by the co-activators SRC-1 and SRC-2, consistent with previous reports (53).

Suppression of Androgen-induced AR Target Gene Expression by DIMN in Prostate Cancer Cells—Because DIMN has anti-androgenic activity, we assessed its effect on the expression of the AR target genes PSA and NKX3.1 (58, 59) in androgen-dependent LNCaP and androgen-independent C4–2 prostate cancer cells (Fig. 3), both of which express functional endogenous AR (60). The mRNA levels of PSA, which is a prostate-specific tumor marker (61), were reduced by treatment with

![FIGURE 3. Effects of DIMN on AR and AR target gene expression in prostate cancer cells. A, suppression of AR target gene expression by DIMN in LNCaP and C4–2 cells. Human prostate cancer LNCaP and C4–2 cells maintained in media containing 5% CSS were treated with 10 μM DIMN or BIC in the absence or presence of 10 nM DHT for 48 h prior to harvest. Total RNA was analyzed by Northern blot analysis using cDNA probes for androgen receptor target genes (PSA and NKX3.1). GAPDH expression was used as an internal control. B, suppression of AR and PSA protein expression by DIMN in LNCaP and C4–2 cells. The protein expression levels of AR and PSA were determined by Western blot analysis. The cells maintained as in A were treated with the indicated concentrations of OHF, BIC, or DIMN in the presence of DHT (LNCaP, 10 nM; C4–2, 1 nM) for 48 h prior to harvest. Specific antibodies against the AR and PSA were used for Western blot analysis. Tubulin or GAPDH expression was used as an internal control.](https://www.jbc.org/content/287/36/30774/F3)
DIMN in the absence or presence of DHT in both LNCaP and C4–2 cells, and this reduction of PSA mRNA levels by DIMN was comparable to or greater than that induced by BIC (Fig. 3A). Interestingly, BIC activated the expression of PSA in the absence of DHT in C4–2 cells, as previously reported in LNCaP (62). The mRNA levels of NKX3.1 showed similar patterns to those of PSA upon DIMN treatment in both LNCaP and C4–2 cells (Fig. 3A).

The change in PSA protein levels was also assessed by Western blot analysis. The expression levels of endogenous PSA induced in the presence of DHT were reduced by treatment with DIMN in a dose-dependent manner in both LNCaP and C4–2 cells (Fig. 3B). DIMN reduced PSA protein levels more effectively than the AR antagonists BIC and OHF at the same concentration (10 μM). Interestingly, DIMN also reduced the protein level of the AR, as previously reported with BIC and OHF (53, 63, 64). Taken together, these results suggest that the compound DIMN inhibits AR function in prostate cancer cells and inhibit the expression of endogenous AR target genes in a similar fashion to the conventional AR antagonists, BIC and OHF.

Inhibition of the Growth of Prostate Cancer Cells by DIMN—To assess the effect of DIMN on the androgen-induced proliferation of prostate cancer cells, we measured the proliferation rate of LNCaP cells by the MTS assay. The growth of LNCaP cells induced by 1 nM DHT was highly inhibited by treatment with 10 μM DIMN as well as with BIC and OHF treatment (Fig. 4A, left panel). To confirm this effect of DIMN on the proliferation rate of LNCaP cells, we also performed thymidine incorporation assay (Fig. 4A, right panel). DNA synthesis, which increased in the presence of DHT, was inhibited ~20 and 60% by 1 μM and 10 μM DIMN, respectively. However, DNA synthesis was inhibited only 10 and 20% by 1 μM and 10 μM BIC, respectively, and up to 15% by OHF. These results indicated that DIMN effectively inhibit the proliferation of LNCaP cells, which represent the early stage androgen-dependent state, and that it is much more potent than BIC or OHF.

To investigate the utility of DIMN as a new generation of AR antagonists for the treatment of CRPC, the more aggressive form of prostate cancer, we next determined the inhibitory effect of DIMN on the proliferation of later stage androgen-independent C4–2 and CWR22rv cells, which grow independently of androgens while expressing AR protein (47, 65). The effect of DIMN on the proliferation rate of C4–2 cells was measured by the MTS assay. The growth of C4–2 cells was effectively inhibited to ~40% by DIMN, which is more potent than the inhibition by BIC at the same dose, 10 μM (Fig. 4B). We also analyzed cell viability by trypan blue staining in CWR22rv cells, because MTS-based assay resulted in an underestimation of the anti-proliferative effect of DIMN in CWR22rv cells due to the limitation of the method as previously described (66). The viability of CWR22rv cells was completely inhibited by DIMN, whereas there was no significant inhibitory effect on cell viability induced by BIC (Fig. 4B). However, the DIMN showed no inhibitory effect on the cell growth of the AR-negative and androgen-independent prostate cancer cell lines PPC-1, DU145, and R3327-AT3.1 (Fig. 4C). Because DIMN also had an inhibitory effect on the growth of androgen-independent prostate cancer cells that express the AR, we investigated the cytotoxicity of DIMN using mouse embryonic fibroblast (MEF) cells as normal cells. The result showed that DIMN exhibited no cytotoxic effect, similar to BIC (Fig. 4D).

**FIGURE 4. Inhibition of the proliferation of prostate cancer cells by DIMN.** A, inhibition of androgen-dependent LNCaP cell growth by DIMN. The inhibitory effect on DHT-induced cell proliferation was evaluated by the MTS colorimetric assay. LNCaP cells seeded into 96-well plates were incubated with 1 nM DHT and 10 μM of the indicated compound for 5 days. The values were compared with those from vehicle-treated cells (left panel). The inhibition of DNA synthesis by DIMN was measured by a [3H]thymidine incorporation assay (right panel). B, inhibition of androgen-independent, but AR-positive, C4–2 and CWR22rv cell growth by DIMN. C4–2 cells were incubated with 1 μM or 10 μM DIMN or BIC for 6 days, and the inhibitory effects on cell proliferation were evaluated by the MTS colorimetric assay (Day 6). CWR22rv cells were incubated with 10 μM DIMN or BIC for 5 days, and cell viability was assessed by trypan blue dye exclusion (Day 5). The white bar represents the starting cell number before chemical treatment (Day 0). Error bars indicate the standard deviation. **, p < 0.01; ***, p < 0.001. C, no inhibitory effect of DIMN was observed on androgen-independent and AR-negative prostate cancer cell growth. For 4 days, PPC-1 and DU145 cells were incubated with 10 μM chemicals, and R3327-AT3.1 cells were incubated with 1 μM or 10 μM chemicals. The inhibitory effects on cell proliferation were evaluated by the MTS colorimetric assay. D, cytotoxic effect of DIMN on MEF cell proliferation. MEF cells were incubated with 10 μM DIMN or BIC in complete medium for 4 days, and the negative effect of DIMN on cell proliferation was evaluated by the MTS colorimetric assay.
Taken together, these results suggest that the synthetic compound DIMN has an effective inhibitory effect on the growth of AR-positive prostate cancer cells, both androgen-dependent (LNCaP) and androgen-independent (C4–2 and CWR22rv), unlike the conventional AR antagonists BIC and OHF.

**Modeling Basis for the Pure Antagonistic Character of DIMN in WT and Mutant ARs**—To investigate the basis for the finding that DIMN acts as a pure AR antagonist in the wild type (WT) and mutated ARs, we predicted the binding mode of DIMN through modeling. A series of AR mutations, including T877A and W741C, has been identified from tissue specimens of CRPC patients. In particular, the T877A mutation has been found in patients who were treated with flutamide and eventually became refractory to the treatment (67). The functional significance of the W741C mutation was demonstrated by the bicalutamide-stimulated tumor growth of a prostate xenograft model derived from bicalutamide-treated patients (68).

The modeling suggested that DIMN fit well into the narrow cavity and formed four possible hydrogen bonds with the backbones of Gln-711 and Arg-752 (Fig. 5A, supplemental Fig. S2). These interactions are identical to agonist R1881 with high AR binding affinity (Fig. 5B), although R1881 forms another hydrogen bond with Thr-877 (69). Despite of the obvious resemblance of DIMN with agonist, the activity exhibited is solely antagonism which is in turn the ability of a compound to displace H12 from AR LBD. BIC in antagonistic mode, as predicted from *in silico* simulations and docking model (30, 70), attains an extended conformation with the sulfonyl-linked phenyl ring orienting away from the indole ring of Trp-741 and facing H12. At this structural orientation, the sulfonyl group of BIC overlaps with Met-895 of H12 and possibly displaces the helix due to a steric clash (72, 73). The steric overlap of other antagonists such as OHF with Thr-877 is believed to cause the conformational change for their antagonism in WT AR (74, 75). However, unexpectedly, BIC has a completely folded conformation with two phenyl rings stacked in the same site that agonist R1881 binds in a docking model (Fig. 5C), which is consistent with the recently illustrated conformation (70). As suggested in the lowest energy state, BIC may act as an agonist even in WT AR, to some extent. The two distinct BIC-AR complexes of either the former extended conformation or the latter folded conformation seem to be accessible due to their comparable binding energy in WT AR (70), presenting a preference of a designed antagonist to have an unfolded scaffold for its full...
antagonism. Moreover, when W741L/W741C mutation occurs, BIC acts as an agonist since the phenyl moiety of BIC shifts up to occupy the cavity created by the absence of the Trp indole and thus allows H12 to fold, and this fashion is similar to the occurrence of point mutation T877A with the switch to agonist from the antagonists (14, 68, 70).

On the other hand, importantly, DIMN has conserved ligand-receptor hydrogen bonds for high AR affinity and an extended linear structure to extrude H12 because of a steric conflict with the bulky isoquinoline ring. It also locates at a distance unaffected by the change in the size of the active site due to point mutation Trp-741 and Thr-877 (Fig. 5D), supporting the assumption that DIMN works as a pure antagonist regardless of WT or mutated AR.

**DISCUSSION**

AR antagonists have proven to be useful targets for chemotherapeutic agents in the treatment of prostate cancer. Non-steroidal AR antagonists, such as bicalutamide, have been widely used because of their selective blockade of androgen action and fewer side effects. However, these antagonists cause some side effects due to an increased serum testosterone level by interrupting the negative feedback regulation in the brain (78) and hormone resistance in advanced prostate tumors (67). Therefore, novel potent AR antagonists with fewer negative effects and working on both hormone-dependent and -independent tumors are highly desirable. In an effort to search for such compounds, we performed AR structure-based virtual screening as a tool to discover a new compound, DIMN. DIMN showed strong AR antagonistic effect and little AR agonistic effect. Considering that the agonistic properties of BIC are thought to cause hormone resistance in advanced prostate tumors (79), our data showing that DIMN has little agonistic effect may suggest that this compound could be developed into more effective AR antagonists for the treatment of advanced prostate cancer.

The AR signaling pathway is essential for the growth and progression of both androgen-dependent and androgen-independent prostate cancers. Because of this, AR-mediated signaling and gene expression have been key targets of advanced prostate cancer therapy through the utilization of anti-androgens that prevent AR activation and/or the disruption of endogenous androgen production (80, 81). However, in most cases, these therapies ultimately fail as a result of AR reactivation by interrupting the negative feedback regulation in the brain and pituitary in common with conventional AR antagonists (78). Therefore, the in vivo study is also necessary to evaluate whether DIMN acts as selective androgen receptor modulators (SARMs), a class of AR antagonists with peripheral tissue selectivity (77). We are currently conducting in vivo experiments.

In summary, we successfully identified a novel chemical entity, the nicotinamide compound DIMN, as a non-steroidal AR antagonist through receptor-based virtual screening. The potent AR antagonism of this compound has been confirmed by AR-ligand binding competition, the blocking of AR activation steps, the reduced expression of AR target genes, and the considerably inhibited proliferation of AR-expressing prostate cancer cells, either androgen-dependent or androgen-independent. The remarkable potency of the action of the compound DIMN on both prostate cancer cell types as well as their strong anti-androgenic activity suggests that this compound could be a potent drug candidate for the treatment of early stage to advanced prostate cancers, potentially replacing currently established anticancer medicines such as BIC.

**Acknowledgments**—We thank Dr. J. W. Lee for the pcDNA3.ERα and ERE-Luc plasmids, Dr. E. M. Wilson for the VP-AR1–660, GAL-AR624–919, and SXGAL4-Luc3 plasmids, Dr. C. Jung for the C4–2 and CWR22rv cells, and Mazence, Inc., for the R3327-AT3.1 cells.
REFERENCES

1. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108
2. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M. J. (2008) Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96
3. Kokontis, J. M., and Liao, S. (1999) Molecular action of androgen in the normal and neoplastic prostate. Vitam. Horm. 55, 219–307
4. Scher, H. I., Steinke, G., and Kelly, W. K. (1995) Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46, 142–148
5. Eder, I. E., Haag, P., Bartsch, G., and Klocker, H. (2005) Targeting the androgen receptor in hormone-refractory prostate cancer—new concepts. Future Oncol. 1, 93–101
6. Heinlein, C. A., and Chang, C. (2004) Androgen receptor in prostate cancer. Endocr. Rev. 25, 276–308
7. Rahman, M., Miyamoto, H., and Chang, C. (2004) Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin. Cancer Res. 10, 2208–2219
8. Setlur, S. R., and Rubin, M. A. (2005) Current thoughts on the role of the androgen receptor and prostate cancer progression. Adv. Anat. Pathol. 12, 265–270
9. Rowland, J. G., Robson, J. L., Simon, W. J., Leung, H. Y., and Slabas, A. R. (2007) Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics 7, 47–63
10. Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., Wu, T., Regan, M. M., Meyer, C. A., Carroll, J. S., Manrai, A. K., Jinne, O. A., Balk, S. P., Mehra, R., Han, B., Chinnaiyan, A. M., Rubin, M. A., True, L., Fiorentino, M., Fiore, C., Loda, M., Kummer, P. W., Liu, X. S., and Brown, M. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245–256
11. Chan, C. D., Welshie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39
12. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Kelninen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, I., and Kallioniemi, O. P. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401–406
13. Edwards, J., Krishna, N. S., Grigor, K. M., and Bartlett, J. M. (2003) Androfolin and Miyamoto, M. (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63, 149–153
14. Tan, J., Shariat, F., Hamil, K. G., Gregory, C. W., Zang, D. Y., Sar, M., Gumerlock, P. H., de Vere White, R. W., Pretlow, T. G., Harris, S. E., Wilson, E. M., Mohler, J. L., and French, F. S. (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 11, 450–459
15. Liu, H., Tchakarov, M., Cato, A. C., Hittmair, A., Radmayer, C., Eberle, J., Bartsch, G., and Klocker, H. (1993) Mutant androgen receptor detected in an advanced-stage prostate carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 7, 1541–1550
16. Weber, M. J., and Goeili, D. (2004) Ras signaling in prostate cancer progression. J. Cell. Biochem. 91, 13–25
17. Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., and Wilson, E. M. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315–4319
18. Clig, Z., Hobisch, A., Cronauer, M. V., Radmayer, C., Bartsch, G., and Klocker, H. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474–5478
19. Chang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isacs, W. B., and Sawyers, C. L. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. U.S.A. 95, 5246–5250
20. Poyet, P., and Labrie, F. (1985) Comparison of the androgenic/anabolic activities of flutamide, cyproterone acetate, and megestrol acetate. Mol. Cell. Endocrinol. 42, 283–288
21. Hamann, L. G., Farmer, L. J., Johnson, M. G., Goldman, M. E., Mais, D. E., Davitian, A., Bender, S. L., and Jones, T. K. (1995) Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists. Ann. N.Y. Acad. Sci. 761, 383–387
22. Reid, P., Kantoff, P., and Oh, W. (1999) Antiandrogens in prostate cancer. Invest. New Drugs 17, 271–284
23. Anderson, J. (2003) The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int. 91, 455–461
24. Wirth, M. P., Hakenberg, O. W., and Froehner, M. (2007) Antiandrogens in the treatment of prostate cancer. Eur. Urol. 51, 306–313
25. Leblanc, E., Diaz Curiel, M., Carrascall, M. T., Méndez-Dávila, C., and de la Piedra, C. (2005) Comparative effects of bicalutamide (Casodex) versus orchidectomy on bone mineral density, bone remodeling, and bone biomechanics in healthy rats. Urol Int. 74, 301–307
26. Söderholm, A. A., Viilulainen, I., Lehtovuori, P. T., Eskelinen, H., Roell, D., Banahmad, A., and Nyrönen, T. H. (2008) Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures. J. Chem. Inf. Modeling 48, 1882–1890
27. Kinoyama, I., Taniguchi, N., Kamimami, E., Nozawa, E., Koutoku, H., Furutani, T., Kudoh, M., and Okada, M. (2005) N-Arylpyrrolizine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists. Chem. Pharm. Bull. 53, 402–409
28. Kinoyama, I., Taniguchi, N., Toyoshima, A., Nozawa, E., Kamikubo, T., Imamura, M., Matsushita, A., Samizu, K., Kawanami, E., Niimi, T., Hamada, N., Koutoku, H., Furutani, T., Kudoh, M., Okada, M., Ohta, M., and Tsukamoto, S. (2006) (+-)(2R,5S)-4-[4-cyano-3-(trifluoromethyl)-phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (YM850) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist. J. Med. Chem. 49, 716–726
29. Jung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., and Wongvipat, J. (2010) Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J. Med. Chem. 53, 2779–2796
30. Lee, Y. S., Kim, H. J., Lee, H. J., Lee, J. W., Chun, S. Y., Ko, S. K., and Lee, K. (2002) Activating signal co-integrator 1 is highly expressed in murine testicular Leydig cells and enhances the ligand-dependent transcriptional activation of androgen receptor. Biol. Reprod. 67, 1580–1587
31. Chattopadhyay, S., Gong, E. Y., Hwang, M., Park, E., Lee, J. H., Hong, C. Y., Choi, H. S., Cheon, J. H., Kwon, H. B., and Lee, K. (2006) The CCAAT enhancer-binding protein-α negatively regulates the transcription of androgen receptor in prostate cancer cells. Mol. Endocrinol. 20, 984–995
32. Shug, J. H., Shong, M., Choi, H. S., and Lee, K. (2008) CR6-interacting factor 1 represses the transcription of androgen receptor by direct interaction. Mol. Endocrinol. 22, 33–46
33. Lee, H. J., Chattopadhyay, S., Gong, E. Y., Ahn, R. S., and Lee, K. (2003) Antiandrogenic effects of bisphenol A and nonylphenol on the function of androgen receptor. Toxicol. Sci. 75, 40–46
39. Ohtake, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270, 1354–1357
40. Hong, H., Kohli, K., Garabedian, M. J., and Stallcup, M. R. (1997) GRIP1, a transcriptional coactivator for the AF-2 transcriptional domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol. 17, 2735–2744
41. Lee, S. K., Anzick, S. L., Choi, J. E., Bubendorf, L., Guan, X. Y., Jung, Y. K., Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., and Balk, S. P. (2002) A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J. Biol. Chem. 277, 34283–34293
42. Langley, E., Kempainen, J. A., and Wilson, E. M. (1998) Intramolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J. Biol. Chem. 273, 92–101
43. Hong, C. Y., Park, J. H., Seo, K. H., Kim, J. M., Im, S. Y., Lee, J. W., Choi, H. S., and Lee, K. (2008) Expression of MIS in the testis is downregulated by tumor necrosis factor α through the negative regulation of SF-1. Mol. Cell. Biol. 23, 6000–6012
44. Yang, J., Bohl, C. E., Nair, V. A., Mustafa, S. M., Miller, D. D., and Dalton, J. T. (2006) Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer. J. Pharmacol. Exp. Ther. 317, 402–408
45. Suh, J. H., Gong, E. Y., Hong, C. Y., Park, E., Ahn, S. R., Park, K. S., and Lee, K. (2008) Reduced testicular steroidogenesis in tumor necrosis factor α knockout mice. J. Steroid Biochem. Mol. Biol. 112, 117–121
46. Hong, C. Y., Gong, E. Y., Kim, K., Suh, J. H., Ko, H. M., Lee, H. J., Choi, H. S., and Lee, K. (2005) Modulation of the expression and transactivation of androgen receptor by the basic helix-loop-helix transcription factor Pod-1 through recruitment of histone deacetylase 1. Mol. Endocrinol. 19, 2245–2257
47. Ai, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., and Wang, Z. (2009) HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol. Endocrinol. 23, 1963–1972
48. Butler, L. M., Agus, D. B., Scher, H. I., J. B., Liu, J., Liu, L., Nelson, J. B., and Dalton, J. T. (2006) GRIP1, a transcriptional coactivator for the AF-2 transcriptional domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol. 17, 2735–2744
49. Lee, H. J., Hwang, M., Chattopadhyay, S., Choi, H. S., and Lee, K. (2008) Evidence that chloramphenicol acetate exhibits androgenic activity in androgen-dependent cell line. Mol. Cell. Endocrinol. 198, 143–147
50. Heinlein, C. A., and Chang, C. (2002) Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23, 175–200
51. Yoon, H. G., and Wong, J. (2006) The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol. Endocrinol. 20, 1048–1060
52. Kemppainen, J. A., and Chang, C. (2002) Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23, 175–200
53. Thalmann, G. N., Sikes, R. A., Wu, T. T., Degeorges, A., Chang, S. M., Ozen, M., Pathak, S., and Chung, L. W. (2000) LNCaP progression model of human prostate cancer: androgen-independence and androgen-insensitivity. Prostate 44, 91–103
54. Kim, J., and Coetzee, G. A. (2004) Prostate specific antigen gene regulation by androgen receptor. J. Cell. Biochem. 93, 233–241
55. Yu, S., Wang, A., and Dong, Z. (2007) A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Molecular Cancer Therapeutics 6, 2057–2064
56. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., and Mulder, E. (1992) Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochimie 74, 2393–2399
57. Furutani, T., Watanabe, T., Tanimoto, K., Hashimoto, T., Koutoku, H., Kudoh, M., Shimizu, Y., Kato, S., and Shikama, H. (2002) Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Biochem. Biophys. Res. Commun. 294, 779–784
58. Lee, S. J., Zhang, Y., Lee, S. D., Jung, C., Li, X., Kim, H. S., Bae, K. H., Jeng, M. H., Kao, C., and Gardner, T. (2004) Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol. Ther. 10, 1051–1058
59. Wang, P., Hanming, S. N., and Heber, D. (2010) Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS one 5, e10202
60. Taplin, M. E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, I., Statler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., and Small, E. J. (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol. 21, 2673–2678
61. Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kanoto, T., and Ogawa, O. (2005) Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 65, 9611–9616
62. Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., Bäsler, S., Schäfer, M., Egner, U., and Carrozzo, M. A. (2000) Structural evidence for lipid specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275, 26164–26171
63. Osoguthorpe, D. J., and Hagler, A. T. (2011) Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry 50, 4105–4113
64. Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J. K., Wart, K., Tam, T., Yang, Y. C., Bañuelos, C. A., Williams, D. E., McEwan, I. J., Wang, Y., and Sadar, M. D. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17, 535–546
65. Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., and Dalton, J. T. (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 6201–6206
66. Bohl, C. E., Miller, D. D., Chen, J. E., Bell, C. E., and Dalton, J. T. (2005) Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. 280, 37747–37754
67. Bohl, C. E., Wu, Z., Miller, D. D., Bell, C. E., and Dalton, J. T. (2007) Crystal structure of the 877A human androgen receptor ligand-binding domain.

Receptor-based Discovery of a Novel AR Antagonist

Térouanne, B., Paris, F., Servant, N., Georges, V., and Sultan, C. (2002) Evidence that chloramphenicol acetate exhibits androgenic activity in androgen-dependent cell line. Mol. Cell. Endocrinol. 198, 143–147

Térouanne, B., Paris, F., Servant, N., Georges, V., and Sultan, C. (2002) Evidence that chloramphenicol acetate exhibits androgenic activity in androgen-dependent cell line. Mol. Cell. Endocrinol. 198, 143–147

Térouanne, B., Paris, F., Servant, N., Georges, V., and Sultan, C. (2002) Evidence that chloramphenicol acetate exhibits androgenic activity in androgen-dependent cell line. Mol. Cell. Endocrinol. 198, 143–147
Receptor-based Discovery of a Novel AR Antagonist

complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. *J. Biol. Chem.* **282**, 13648–13655

75. Salvati, M. E., Balog, A., Shan, W., Wei, D. D., Pickering, D., Attar, R. M., Geng, J., Rizzo, C. A., Gottardis, M. M., Weinmann, R., Krystek, S. R., Sack, J., An, Y., and Kish, K. (2005) Structure-based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. *Bioorganic Medicinal Chemistry Letters* **15**, 271–276

76. Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C. D., Higano, C. S., Beer, T. M., Hung, D. T., Scher, H. I., Jung, M. E., and Sawyers, C. L. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* **324**, 787–790

77. Mohler, M. L., Bohl, C. E., Jones, A., Coss, C. C., Narayanan, R., He, Y., Hwang, D. J., Dalton, J. T., and Miller, D. D. (2009) Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. *J. Med. Chem.* **52**, 3597–3617

78. Miyamoto, H., Messing, E. M., and Chang, C. (2004) Androgen deprivation therapy for prostate cancer: current status and future prospects. *Prostate* **61**, 332–353

79. Culig, Z., Hoffmann, J., Erdel, M., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., and Klocker, H. (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. *Br. J. Cancer* **81**, 242–251

80. Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., and French, F. S. (1998) Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. *Cancer Res.* **58**, 5718–5724

81. Craft, N., and Sawyers, C. L. (1998) Mechanistic concepts in androgen-dependence of prostate cancer. *Cancer Metastasis Rev.* **17**, 421–427

82. Grigoryev, D. N., Long, B. J., Njar, V. C., and Brodie, A. H. (2000) Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. *J. Steroid Biochem. Mol. Biol.* **75**, 1–10

83. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 5458–5463

84. Kang, H. Y., Lin, H. K., Hu, Y. C., Yeh, S., Huang, K. E., and Chang, C. (2001) From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 3018–3023

85. Miyamoto, H., Yeh, S., Wilding, G., and Chang, C. (1998) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 7379–7384

86. Miyamoto, H., Yeh, S., Shima, H., and Chang, C. (1998) From estrogen to androgen receptor: a new pathway for sex hormones in prostate. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 5527–5532

87. Wang, Y., Romigh, T., He, X., Orloff, M. S., Silverman, R. H., Heston, W. D., and Eng, C. (2010) Rvateratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and-independent mechanisms in prostate cancer cell lines. *Hum. Mol. Genetics* **19**, 4319–4329

88. Feldman, B. J., and Feldman, D. (2001) The development of androgen-independent prostate cancer. *Nat. Reviews Cancer* **1**, 34–45

89. Rodriguez-Berriguete, G., Fraile, B., Martinez-Onsurbe, P., Olmedilla, G., Paniagua, R., and Royuela, M. (2012) MAP Kinases and Prostate Cancer. *J. Signal Transduction* **2012**, 169170

90. Manin, M., Baron, S., Goossens, K., Beaudoin, C., Jean, C., Veyssiere, G., Verhoeven, G., and Morel, L. (2002) Androgen receptor expression is regulated by the phosphoinositol 3-kinase/Akt pathway in normal and tumoral epithelial cells. *Biochem. J.* **366**, 729–736

91. Wen, Y., Hu, M. C., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D. H., and Hung, M. C. (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. *Cancer Res.* **60**, 6841–6845

92. Lin, H. K., Yeh, S., Kang, H. Y., and Chang, C. (2001) Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 7200–7205

93. Sharma, M., Chuang, W. W., and Sun, Z. (2002) Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. *J. Biol. Chem.* **277**, 30935–30941

94. Eng, C. (2003) PTEN: one gene, many syndromes. *Human Mutation* **22**, 183–198

95. Mikhailova, M., Wang, Y., Bedolla, R., Lu, X. H., Kreisberg, I. J., and Ghosh, P. M. (2008) Akt regulates androgen receptor-dependent growth and PSA expression in prostate cancer. *Adv. Exp. Med. Biol.* **617**, 397–405

96. Wang, Y., Mikhailova, M., Bose, S., Pan, C. X., de Vere White, R. W., and Ghosh, P. M. (2008) Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. *Oncogene* **27**, 7106–7117

97. Ghosh, P. M., Malik, S. N., Bedolla, R. G., Wang, Y., Mikhailova, M., Prihoda, T. J., Troyer, D. A., and Kreisberg, I. J. (2005) Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. *Endocr. Relat. Cancer* **12**, 119–134